

## **Combined injection NETE+TU for male contraception**

**Introduction:** The paper on the Efficacy and Safety of an Injectable contraception hormonal treatment for men reported on the results of a multi-center study that evaluated intramuscular injections of 200mg of NET-EN and 1000mg of Testosterone acetate administered every 8 weeks in 320 participants enrolled from 10 study centers. The study regimen led to near-complete and reversible suppression of spermatogenesis. The contraceptive efficacy was good compared with other reversible methods available for men, with a reported pregnancy rate of 1.57 per 100 continuing users. The frequencies of mild to moderate mood disorders were relatively high. This led to the discontinuation of the study as advised by the Research Protocol Review Panel of WHO RHR.

**Objective:** This secondary analyses looks at the profile of additional hormones, not yet reported in the first paper, including free testosterone, DHT and NET levels, and the correlations of hormone levels and their changes with the occurrence of selected adverse events, related to mood and libido.

**Methods:** secondary analyses

**Results:** The mean values of free testosterone, DHT and NET at baseline, at the last suppression phase visit, at the end of the efficacy phase and at the end of recovery phase and study period were reported. Testosterone and DHT levels were markedly suppressed at the end of the study compared to the baseline, while NET was elevated. Hormone levels will be assessed with the occurrence of libido changes, mood disorders and depression.

**Conclusions:** Hormones would need to be monitored at key phases of sperm suppression studies using hormones for contraceptive purposes. Key mood and affect changes take place as influenced by hormonal changes, and by continuous suppression.

**Presenter biography:** Mario Festin is an obstetrician gynecologist, clinical epidemiologist and health professions educator, presently working as a Medical Officer in the Department of Reproductive Health and Research at the World Health Organization, in the Human Reproduction Team, working on Family Planning. Areas of focus include human resources training and programming, scaling up and implementation guidance, and contraceptive research and development.

Do the author(s) have any commercial interests or associations that might pose a conflict of interest regarding this submission? :

No, COI

**Author:**  
Mario Festin  
WHO  
Switzerland